In the search for superior growth stocks, many investors turn to systematic approaches that filter for specific financial characteristics. One such method is outlined in Louis Navellier's "The Little Book That Makes You Rich," which details eight fundamental rules made to identify companies with strong and accelerating business momentum. The strategy focuses on concrete metrics like earnings revisions, sales growth, margin expansion, and return on equity, aiming to find firms before their growth potential is fully recognized by the broader market.
A recent screen based on this methodology has highlighted XOMA ROYALTY CORP - XOMA 8 5/8 PERP (NASDAQ:XOMAP) as a potential candidate. As a biotech royalty aggregator, XOMA's business model involves acquiring economic rights to therapeutic candidates, providing it with a diversified stream of potential future royalties from partnered drug development programs.
Alignment with the "Little Book" Growth Criteria
The screen uses Navellier's eight rules as filters. A review of XOMAP's recent financial performance shows it meets several of these strict growth-oriented conditions, which are important for identifying companies with positive operational momentum.
- Positive Earnings Revisions: Analysts have significantly raised their estimates for the next quarter's earnings per share (EPS) by 126.3% over the last three months. This upward revision is a primary signal in Navellier's strategy, suggesting analysts have growing confidence in the company's near-term profitability.
- Positive Earnings Surprises: The company has not only beaten EPS estimates in each of the last four quarters but has done so by a substantial average margin of 623.8%. Consistent positive surprises can force the market to re-evaluate a company's future earnings potential.
- Increasing Sales Growth: Accelerating revenue is a cornerstone of growth investing. XOMAP shows strong sales momentum with a 74.0% increase in revenue over the past year and a 57.9% jump in the most recent quarter compared to the same period last year.
- Expanding Operating Margin: Profitability is improving markedly. The company's operating margin has grown by 152.5% over the past year, indicating it is converting a much larger portion of its rising sales into operating income.
- Strong Cash Flow & Earnings Growth: The firm's free cash flow surged by 108.5% in the past year, providing financial flexibility. This is complemented by high earnings growth, with EPS soaring 170.9% year-over-year and 157.8% in the latest quarter.
- High Return on Equity (ROE): With an ROE of 17.8%, the company clears the strategy's hurdle of 10%. This indicates efficient use of shareholder capital to generate profits, a key attribute for a sustainable growth enterprise.
Fundamental Health and Valuation Context
A review of XOMAP's broader fundamental profile, as detailed in its detailed analysis report, presents a mixed but interesting picture. The company earns an overall fundamental rating of 6 out of 10. Its strengths are pronounced in growth and profitability, where it scores highly. Margins are solid and significantly outperform most industry peers, while its return on equity and assets are also strong.
The valuation picture is nuanced. While its price-to-earnings (P/E) ratio appears expensive in isolation, it is actually lower than the vast majority of its biotechnology industry peers. Investors are also compensated with a substantial dividend yield of 8.37%. However, areas of concern exist, primarily related to financial health, where the score is average. The company carries a notable debt load, and some solvency metrics, such as its Altman-Z score, signal risk, though they are not uncommon for the development-stage biotech sector.
Investment Considerations and Next Steps
For investors using a growth-focused strategy like Navellier's, XOMAP presents an interesting case based on its exceptional operational momentum across sales, earnings, and cash flow. The company is performing strongly on the metrics that growth screens are made to find. However, the investment thesis is balanced by the company's financial leverage and the inherent risks associated with its royalty model, which depends on the success of partners' clinical trials.
The current market environment, with both long and short-term trends for the S&P 500 in negative territory, highlights the importance of careful fundamental selection. Stocks demonstrating independent fundamental strength, as this screen aims to find, may be better positioned during broader market weakness.
This analysis of XOMA Royalty Corp originated from a systematic stock screen. Investors interested in exploring other companies that currently pass similar growth filters can review the full screen and its results here.
,
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer or solicitation to buy or sell any securities. The information presented should not be used as the sole basis for any investment decision. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.